1Surveillance, Prevention, and Health Services Research, American Cancer Society, Atlanta, Georgia. *Corresponding Author: Elizabeth J. Schafer, Surveillance ...

1Cancer Metastasis Laboratory, University College London Cancer Institute, London, United Kingdom. 2Cancer Research UK Lung Cancer Centre of Excellence, UCL Cancer Institute, London, United Kingdom.

AACR Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Cancer Research Communications ...

1941 1942 1943 1944 1945 1946 1947 1948 1949 1950 1951 1952 1953 1954 1955 1956 1957 1958 1959 1960 1961 1962 1963 1964 1965 1966 1967 1968 1969 1970 1971 1972 1973 ...

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia. *Corresponding Author: Priti Bandi, Risk Factors and Screening Research, Surveillance and Health Equity Science, ...

AACR Journals Blood Cancer Discovery Cancer Discovery Cancer Epidemiology, Biomarkers & Prevention Cancer Immunology Research Cancer Prevention Research Cancer Research Cancer Research Communications ...

2020 Meetings Abstracts: AACR Special Conference on Advancing Precision Medicine Drug Development: Incorporation of Real-World Data and Other Novel Strategies January 9–12, 2020; San Diego, CA ...

The tumor suppressor p53 is activated by a range of cellular stresses including DNA damage, oncogenic signals, and nutrient deprivation. Upon activation, p53 transcriptionally upregulates an extensive ...

Summary and Conclusions. A cigarette tar condensate was obtained with a smoking machine which simulated human smoking habits. The resulting tar was dissolved in acetone and applied to the backs of ...

1 Department of Medicine and Pathology, College of Physicians and Surgeons, Columbia University, and the Presbyterian Hospital, New York City ...

Department of Gastrointestinal Surgery, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou, China.

Divarasib plus cetuximab is well tolerated in patients with KRAS G12C-positive colorectal cancer.